StockData
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. (IMMX) company profile

IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.20−0.28 (-3.74%)

Close on Nov 17, 2026Market cap $515.08MP/E –Yield –

About Immix Biopharma

Pharmaceutical Preparations, SIC 2834

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops chimeric antigen receptor cell therapies to treat light chain amyloidosis and other serious medical conditions. Its research focuses on utilizing its proprietary cell therapy platform to create therapeutic candidates. The company's lead product candidate is NXC-201, an investigational cell therapy designed for individuals suffering from relapsed or refractory light chain amyloidosis. Immix Biopharma operates in the biopharmaceutical industry and directs its therapeutic programs toward patient populations diagnosed with these critical disorders.

The company conducts its clinical and operational activities across the United States and internationally. It maintains a wholly-owned research and development subsidiary located in Australia. Clinical trials evaluating its lead cell therapy candidate take place at study sites within the United States as well as international locations. Immix Biopharma is incorporated in Delaware and maintains its corporate headquarters in Los Angeles, California.

Summary of the business section of Immix Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Immix Biopharma, Inc.
Headquarters
Los Angeles, CA
Address
11400 West Olympic Blvd., Suite 200 90064
Phone
(888) 958-1084
Employees
21, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Crowe LLP, Los Angeles, California

Stock & identifiers

Ticker
IMMX
Exchange
Nasdaq
IPO date
Dec 17, 2021
Shares outstanding
72M, Aug 3, 2026
Public float
$35.71M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1873835
CUSIP
45258H106
ISIN
US45258H1068
FIGI
BBG00HLCWH09
Share class FIGI
BBG00HLCWH18
EIN
45-4869378

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ilya M. RachmanCEO and Chairman, Director1,141,683
Gabriel S. MorrisCFO, President, Director718,273
Jane BuchanDirector28,705
Helen C. AdamsDirector181,004
Magda MarquetDirector72,342
Jason HsuDirector4,815,163
Nancy T. ChangDirector925,130
Carey NgDirector1,051,471
Yekaterina ChudnovskyDirector3,247,326

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payTotalvs. prior year
Ilya Rachman
Chief Executive Officer
$475.00K$592.85K$285.00K$1.35M+7%
Gabriel Morris
Chief Financial Officer
$475.00K$592.85K$285.00K$1.35M+7%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 17, 2021
Offer price
$5.00
Securities offered
4,200,000
Gross proceeds
$21.00M
Exchange
Nasdaq
First trading day
Dec 16, 2021
First-day close
$3.67-26.6%
Lock-up ends (est.)
Jun 14, 2022

“The initial public offering price of our common stock is $5.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of March 20, 2026, we had 21 employees, all of which are full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?